

CHAIRMAN'S ADDRESS

Bionomics AGM – 4 November 2009

I have been honoured and delighted to serve as your Chairman for the past 5 years.

It has been an exciting time for the company:

- We made a major strategic move from genomics to drug development
- We made two bold acquisitions which have already paid off and which I am confident will deliver even greater returns in the future.
- We have one drug candidate in phase two testing with patients and another in phase one - both with potential application to severe conditions and massive markets.
- There is a pipeline of further possible drug candidates that your CEO, Dr Deborah Rathjen, will discuss shortly.
- We have signed deals with several big pharma companies that have already delivered revenue and that have considerable further potential
- We have been consistently supported by you, the shareholders, providing fresh capital for each strategic move, most recently by a capital raising this year of approximately \$19 million.

Naturally, we all understand that in the drug development business there can be no certainties - this is a high risk, high return business.

But I believe Bionomics has highly professional and dedicated management and sound risk management practices.


I feel confident that Bionomics can fight through to a point where it becomes another example of Australia's great tradition of medical research reducing pain and suffering for many individuals and producing great rewards for its shareholders.

I leave a well capitalised company with great prospects.

Your new Chairman, Chris Fullerton, will provide strong leadership appropriate for the next phase of the company's development.

I wish the company every good fortune and thank the staff, members of the board and shareholders for your strong support.

Yours sincerely



Peter Jonson